摘要
临床研究证实术后辅助化疗能显著降低可手术乳腺癌患者的病死率，提高生存率。目前乳腺癌辅助化疗正朝着特异性、高效性及低毒性方向发展。基于分子遗传学分析的个体化、规范化综合治疗是今后乳腺癌辅助化疗治疗的方向。
Clinical studies confirm that postoperative adjuvant chemotherapy could significantly reduce mortality rate of patients with the operable breast cancer and improve surviral rate. At present, adjuvant chemotherapy of breast cancer is developing for the direction of high specificity, more efficiency and low toxicity. Individualized and standardized comprehensive treatment which based on molecular genetic analysis is the direction of adjuvant chemotherapy of breast cancer.
出处
《国际肿瘤学杂志》
CAS
2011年第8期605-608,共4页
Journal of International Oncology
关键词
乳腺肿瘤
药物疗法
辅助化疗
Breast neoplasms
Chemotherapy
Adjuvant chemotherapy
